Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="181964.fig.001a" src="https://static.hindawi.com/articles/au/volume-2012/181964/figures/181964.fig.001a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Bladder cancer recurrence</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="181964.fig.001b" src="https://static.hindawi.com/articles/au/volume-2012/181964/figures/181964.fig.001b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Bladder cancer progression (EGFR)</td></tr></table></td></tr></table>

<table>Forest plots of studies on the prognostic significance of EGFR and ErbB2 overexpression in bladder cancer. (a) The effect on recurrence. (b) The effect of EGFR (A) or ErbB2 (B) on progression. Hazard ratios and 95%  (confidence intervals) CIs for patients with either EGFR- or ErbB2-positive tumors.</table>

Advances in Urology

fig1

Figure 1

Figure 1: Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis 